reports
Basilea Pharmaceutica AG: 1 director
A director at Basilea Pharmaceutica AG sold 2,514 shares at 41.008CHF and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Basilea-Aktionäre genehmigen an der Generalversammlung alle Anträge de...
Basilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des Verwaltungsrats Allschwil, 24. April 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab bekannt, dass die Aktionärinnen und Aktionäre an der heutigen ordentlichen Generalversammlung (GV) für das Geschäftsjahr 2023 allen vom Verwaltungsrat vorgeschlagenen Anträgen zugestimmt haben. An der GV genehmigten die Aktionäre den Lagebericht, d...
Basilea shareholders approve all proposals of the board of directors a...
Basilea shareholders approve all proposals of the board of directors at the annual general meeting Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2023. At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for t...
- Sean Conroy
Basilea Pharmaceutica - Need for innovation against severe infections
At its recent capital markets day (CMD) and with the support of key opinion leaders, Basilea highlighted the rising need for innovative therapies to address serious fungal and bacterial infections. It continues to make advancements in this specialised segment through the development of opportunistic acquisitions leveraging its anti-infective expertise. Its growth initiatives remain funded through the traction of its commercialised products, Cresemba and Zevtera. FY24 key strategic priorities inc...
- Sean Conroy
Basilea Pharmaceutica - CARB-X grant for preclinical programs
In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership backed by governments and foundations, for its preclinical antibiotics program. CARB-X is focused on supporting early-stage antibacterial research and development, and this grant is expected to support development work up until clinical candid...
Basilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erw...
Basilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-Wirkstoffklasse Allschwil, 09. April 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass das Unternehmen Fördergelder von CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) erhält, einer global agierenden, gemeinnützigen partnerschaftlichen Initiative, welche die Frühph...
Basilea awarded CARB-X grant to develop recently acquired novel class ...
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant award is to support initial preclinical ...
- Sean Conroy
Basilea Pharmaceutica - Zevtera crosses key US regulatory hurdle
Basilea has announced the FDA approval of its second lead asset, Zevtera (ceftobiprole), for the treatment of severe bacterial infections (three indications), marking a major commercial win. The US is the most commercially lucrative market for Zevtera, accounting for 85–90% of its total market potential. Zevtera is already approved in several countries (including in Europe) and the FDA nod is based on three Phase III studies (including the ERADICATE and TARGET studies with R&D partly funded by t...
- Oscar Haffen Lamm
Basilea: Zevtera to enter US market after FDA approval
Yesterday after market close, the FDA announced that it approved the use of Zevtera (ceftobiprole) in three indications, namely i) in adults with Staphylococcus aureus bloodstream infections (SAB), including those with right-sided infective endocarditis, ii) in adults with acute bacterial skin and
Basilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ce...
Basilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekannt Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 04. April 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde Food and Drug Administration (FDA) das Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril-Natrium zur Injektion) die Zulassung...
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole...
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the US Food and Drug Administration (FDA) approved ZEVTERA® (ceftobiprole medocaril sodium for injection), for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bactere...
- Sean Conroy
Basilea Pharmaceutica - Strong Cresemba traction triggers milestone pa...
Continued strong sales of Cresemba, Basilea Pharmaceutica’s lead antifungal asset, in the Asia-Pacific region and China, has triggered the receipt of a US$1.25m milestone payment from Pfizer (license partner). This comes on the heels of Basilea’s first sales-related milestone from distribution partner Knight Therapeutics in January for sales in Latin America. We believe these reflect sustained market traction for Cresemba, leading to in-market sales of US$445m in the 12 months ending September 2...
Anhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pa...
Anhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus Allschwil, 11. März 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass die anhaltend guten Verkäufe des Antimykotikums Cresemba® (Isavuconazol) durch Basileas Lizenzpartner Pfizer Inc. in der Region Asien-Pazifik und China die Schwelle überschritten haben, d...
Continued strong Cresemba® (isavuconazole) sales performance in Asia P...
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone...
- Sean Conroy
Basilea Pharmaceutica - From strength to strength
FY23 was another strong year for Basilea, marked by successive guidance beats and meaningful progress in fortifying its product pipeline. Revenues of CHF157.6m were ahead of guidance, driven by c 23% y-o-y growth in Cresemba- and Zevtera-related revenues to CHF150.3m. Top-line growth, combined with operational prudence (despite investments in growing its portfolio), supported Basilea in achieving a second successive year of net profitability (CHF10.5m, c 2x the guided figure). FY24 will be an im...
Basilea meldet starkes Gesamtjahr 2023 mit einer über der Guidance lie...
Basilea meldet starkes Gesamtjahr 2023 mit einer über der Guidance liegenden Profitabilität trotz substanziell erweitertem F&E-Portfolio Anstieg der Cresemba®- und Zevtera®-basierten Umsätze auf CHF 150.3 Mio. (+22.9 % gegenüber dem Vorjahr), was am oberen Ende der Guidance liegtBetriebsgewinn von CHF 19.2 Mio. und Gewinn von CHF 10.5 Mio., beides deutlich über der GuidanceErweiterung des klinischen Portfolios um drei neue Antiinfektiva, darunter das Phase-3-bereite Antimykotikum FosmanogepixStarke Cash-Position mit liquiden Mitteln und liquiden Mitteln mit Verfügungsbeschränkung in Höhe vo...
Basilea reports strong 2023 full-year results with profitability signi...
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million and net profit of CHF 10.5 million, significantly above guidanceAddition of three new anti-infective assets to clinical portfolio, including phase-3-ready antifungal fosmanogepixStrong cash and restricted cash position of CHF 64.3 million, after fully absorbing investments into portfolio expansion a...
- Maria Vara
- Oscar Haffen Lamm
Coverage update
Given team and strategy changes, Oscar Haffen Lamm is now assuming coverage of Medincell, Camurus, Valneva, Aelis Pharma, Abivax, Calliditas, Egetis Therapeutics, Basilea, Geneuro, Achilles, Valerio, Innate Pharma, Morphosys, Inventiva Pharma, Vicore, DBV Technologies, and Genfit.Maria Vara is now
BSLN BASILEA PHARMACEUTICA AG
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ALMDT MEDIAN TECHNOLOGIES
EGTX EGETIS THERAPEUTICS AB
7CA CAMURUS AB
VICO VICORE PHARMA HOLDING AB
5142 ACHILLES CORP.
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
XVIVO XVIVO PERFUSION AB
GNRO GENEURO SA
BONEX BONESUPPORT HOLDING AB
MOR MORPHOSYS AG
MED MEDARTIS AG
MEDCL MEDINCELL SA
CALTX CALLIDITAS THERAPEUTICS AB
IVA INVENTIVA ADS
CLNK B CELLINK AB
GNFT GENFIT
AELIS AELIS FARMA SA
ONWD ONWARD OPPORTUNITIES LIMITED
ALONX ONXEO
ABVX ABIVAX
- Sean Conroy
Basilea Pharmaceutica - Strong close to FY23 with another milestone pa...
Basilea has announced receipt of its first sales-related milestone (for an undisclosed amount) from distribution partner Knight Therapeutics. The payment was triggered by combined Cresemba sales in Latin America exceeding a pre-defined sales threshold. Cresemba continues to see strong market traction for the treatment of invasive aspergillosis and mucormycosis, with the drug reporting in-market sales of US$445m in the 12 months ending September 2023 (+22% y-o-y), reflecting a growing market shar...
Cresemba®-Verkaufszahlen in Lateinamerika lösen erste Umsatzmeilenstei...
Cresemba®-Verkaufszahlen in Lateinamerika lösen erste Umsatzmeilensteinzahlung an Basilea aus Allschwil, 19. Januar 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass die Verkaufszahlen ihres Partners Knight Therapeutics Inc. («Knight», TSX: GUD) für das Antimykotikum Cresemba® (Isavuconazol) in Lateinamerika im Jahr 2023 die Schwelle überschritten haben, durch die eine erste Umsatzme...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.